Social and Clinical Determinants of Contralateral Prophylactic Mastectomy
- PMID: 24849045
- PMCID: PMC4703398
- DOI: 10.1001/jamasurg.2013.5689
Social and Clinical Determinants of Contralateral Prophylactic Mastectomy
Abstract
Importance: The growing rate of contralateral prophylactic mastectomy (CPM) among women diagnosed as having breast cancer has raised concerns about potential for overtreatment. Yet, there are few large survey studies of factors that affect women's decisions for this surgical treatment option.
Objective: To determine factors associated with the use of CPM in a population-based sample of patients with breast cancer.
Design, setting, and participants: A longitudinal survey of 2290 women newly diagnosed as having breast cancer who reported to the Detroit and Los Angeles Surveillance, Epidemiology, and End Results registries from June 1, 2005, to February 1, 2007, and again 4 years later (June 2009 to February 2010) merged with Surveillance, Epidemiology, and End Results registry data (n = 1536). Multinomial logistic regression was used to evaluate factors associated with type of surgery. Primary independent variables included clinical indications for CPM (genetic mutation and/or strong family history), diagnostic magnetic resonance imaging, and patient extent of worry about recurrence at the time of treatment decision making.
Main outcomes and measures: Type of surgery received from patient self-report, categorized as CPM, unilateral mastectomy, or breast conservation surgery.
Results: Of the 1447 women in the analytic sample, 18.9% strongly considered CPM and 7.6% received it. Of those who strongly considered CPM, 32.2% received CPM, while 45.8% received unilateral mastectomy and 22.8% received breast conservation surgery (BCS). The majority of patients (68.9%) who received CPM had no major genetic or familial risk factors for contralateral disease. Multivariate regression showed that receipt of CPM (vs either unilateral mastectomy or breast conservation surgery) was significantly associated with genetic testing (positive or negative) (vs UM, relative risk ratio [RRR]: 10.48; 95% CI, 3.61-3.48 and vs BCS, RRR: 19.10; 95% CI, 5.67-56.41; P < .001), a strong family history of breast or ovarian cancer (vs UM, RRR: 5.19; 95% CI, 2.34-11.56 and vs BCS, RRR: 4.24; 95% CI, 1.80-9.88; P = .001), receipt of magnetic resonance imaging (vs UM RRR: 2.07; 95% CI, 1.21-3.52 and vs BCS, RRR: 2.14; 95% CI, 1.28-3.58; P = .001), higher education (vs UM, RRR: 5.04; 95% CI, 2.37-10.71 and vs BCS, RRR: 4.38; 95% CI, 2.07-9.29; P < .001), and greater worry about recurrence (vs UM, RRR: 2.81; 95% CI, 1.14-6.88 and vs BCS, RRR: 4.24; 95% CI, 1.80-9.98; P = .001).
Conclusions and relevance: Many women considered CPM and a substantial number received it, although few had a clinically significant risk of contralateral breast cancer. Receipt of magnetic resonance imaging at diagnosis contributed to receipt of CPM. Worry about recurrence appeared to drive decisions for CPM although the procedure has not been shown to reduce recurrence risk. More research is needed about the underlying factors driving the use of CPM.
Conflict of interest statement
None of the authors have conflicts of interest to disclose.
Figures
Comment in
-
Contralateral Prophylactic Mastectomy: An Opportunity for Shared Decision Making.JAMA Surg. 2014 Jun;149(6):589-90. doi: 10.1001/jamasurg.2013.5713. JAMA Surg. 2014. PMID: 24848646 Free PMC article. No abstract available.
Similar articles
-
Contralateral Prophylactic Mastectomy Decisions in a Population-Based Sample of Patients With Early-Stage Breast Cancer.JAMA Surg. 2017 Mar 1;152(3):274-282. doi: 10.1001/jamasurg.2016.4749. JAMA Surg. 2017. PMID: 28002555 Free PMC article.
-
Surgeon Influence on Variation in Receipt of Contralateral Prophylactic Mastectomy for Women With Breast Cancer.JAMA Surg. 2018 Jan 1;153(1):29-36. doi: 10.1001/jamasurg.2017.3415. JAMA Surg. 2018. PMID: 28903158 Free PMC article.
-
Surgical Decision-Making Surrounding Contralateral Prophylactic Mastectomy: Comparison of Treatment Goals, Preferences, and Psychosocial Outcomes from a Multicenter Survey of Breast Cancer Patients.Ann Surg Oncol. 2021 Dec;28(13):8752-8765. doi: 10.1245/s10434-021-10426-y. Epub 2021 Jul 12. Ann Surg Oncol. 2021. PMID: 34251554 Free PMC article.
-
Prophylactic mastectomy for the prevention of breast cancer.Cochrane Database Syst Rev. 2004 Oct 18;(4):CD002748. doi: 10.1002/14651858.CD002748.pub2. Cochrane Database Syst Rev. 2004. Update in: Cochrane Database Syst Rev. 2010 Nov 10;(11):CD002748. doi: 10.1002/14651858.CD002748.pub3 PMID: 15495033 Updated. Review.
-
Contralateral prophylactic mastectomy for patients with unilateral breast cancer.Expert Rev Anticancer Ther. 2007 Aug;7(8):1117-22. doi: 10.1586/14737140.7.8.1117. Expert Rev Anticancer Ther. 2007. PMID: 18028020 Review.
Cited by
-
Patient Preference for Surgical Methods for Ipsilateral Breast Tumor Recurrence.Ann Surg Oncol. 2024 Jul;31(7):4512-4517. doi: 10.1245/s10434-024-15282-0. Epub 2024 Apr 9. Ann Surg Oncol. 2024. PMID: 38594578
-
Contralateral prophylactic mastectomy in a rural population: A single-institution experience.Surg Open Sci. 2024 Feb 23;18:70-77. doi: 10.1016/j.sopen.2024.02.007. eCollection 2024 Mar. Surg Open Sci. 2024. PMID: 38435489 Free PMC article.
-
Contralateral prophylactic mastectomy for unilateral breast cancer in Chinese female population: a retrospective cohort study.Gland Surg. 2023 Dec 26;12(12):1668-1685. doi: 10.21037/gs-23-384. Epub 2023 Dec 22. Gland Surg. 2023. PMID: 38229836 Free PMC article.
-
Long-term outcomes of young, node-negative, chemotherapy-naïve, triple-negative breast cancer patients according to BRCA1 status.BMC Med. 2024 Jan 9;22(1):9. doi: 10.1186/s12916-023-03233-7. BMC Med. 2024. PMID: 38191387 Free PMC article.
-
The Incidence and Outcomes of Breast Implants Among 1696 Women over more than 50 Years.Aesthetic Plast Surg. 2023 Dec;47(6):2268-2276. doi: 10.1007/s00266-023-03535-4. Epub 2023 Aug 14. Aesthetic Plast Surg. 2023. PMID: 37580563 Review.
References
-
- Lostumbo L, Carbine NE, Wallace J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev. 2010;(11):CD002748. - PubMed
-
- Giuliano AE, Boolbol S, Degnim A, et al. Society of Surgical Oncology: position statement on prophylactic mastectomy. Approved by the Society of Surgical Oncology Executive Council, March 2007. Ann Surg Oncol. 2007;14(9):2425–2427. Epub 2007 Jun 28. - PubMed
-
- Tuttle TM, Abbott A, Arrington A, Rueth N. The increasing use of prophylactic mastectomy in the prevention of breast cancer. Curr Oncol Rep. 2010;12:16–21. - PubMed
-
- Herrinton LJ, Barlow WE, Yu O, et al. Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project. J Clin Oncol. 2005;23:4275–4286. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
